secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001193125-23-044204
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

NICE recommends Vir's sotrovimab for COVID-19 in UK; no meaningful 2023 sales expected
--------------------------------------------------------------------------------

- NICE final draft guidance recommends sotrovimab for high-risk adults where Paxlovid is contraindicated or unsuitable.
- Recommendation based on cost-effectiveness evaluation of sotrovimab.
- No meaningful additional UK sales of sotrovimab anticipated in 2023 due to existing inventory.
- Sotrovimab (Xevudy) authorized in over 40 countries; not authorized in the US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523044204/0001193125-23-044204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523044204/d444727d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-044204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer